Cite
HARVARD Citation
Albisetti, M. et al. (2018). Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism. Research and practice in thrombosis and haemostasis. 2 (1), pp. 69-76. [Online].